Editing Pyrosequencing (section)

==Commercialization==

The company '''Pyrosequencing AB''' in [[Uppsala, Sweden]] was founded with [[venture capital]] provided by [[HealthCap]] in order to commercialize machinery and reagents for sequencing short stretches of DNA using the pyrosequencing technique. Pyrosequencing AB was listed on the [[Stockholm Stock Exchange]] in 1999. It was renamed to Biotage in 2003.<ref>{{Cite web |last=Biotage |title=Biotage History |url=https://www.biotage.com/biotage-history |access-date=2022-09-19 |website=www.biotage.com |language=en}}</ref> The pyrosequencing business line was acquired by [[Qiagen]] in 2008.  Pyrosequencing technology was further licensed to [[454 Life Sciences]]. 454 developed an array-based pyrosequencing technology which emerged as a platform for [[DNA sequencing#High-throughput sequencing|large-scale DNA sequencing]], including [[genome project|genome sequencing]] and [[metagenomics]].

[[Hoffmann-La Roche|Roche]] announced the discontinuation of the 454 sequencing platform in 2013.<ref>{{cite news|last1=Hollmer|first1=Mark|title=Roche to close 454 Life Sciences as it reduces gene sequencing focus |url=http://www.fiercebiotech.com/medical-devices/roche-to-close-454-life-sciences-as-it-reduces-gene-sequencing-focus|work=Fierce Biotech|date=October 17, 2013}}</ref>